orlistat mutoh et al 1994 the term u201c lipase inhibitor u201d refers also to polymer bound lipase inhibitors for example described in international patent application wo99 34786 geltex pharmaceuticals inc these polymers are characterized in that they have been substituted with one or more groups that inhibit lipases the term u201c lipase inhibitor u201d also comprises pharmaceutically acceptable salts of these compounds the term u201c lipase inhibitor u201d preferably refers to orlistat orlistat is a known compound useful for the control or prevention of obesity and hyperlipidemia see u s pat no 4 598 089 issued jul 1 1986 which also discloses processes for making orlistat and u s pat no 6 004 996 which discloses appropriate pharmaceutical compositions further suitable pharmaceutical compositions are described for example in international patent applications wo 00 09122 and wo 00 09123 additional processes for the preparation of orlistat are disclosed in european patent applications publication nos 185 359 189 577 443 449 and 524 495 orlistat is preferably orally administered from 60 to 720 mg per day in divided doses two to three times per day preferred is wherein from 180 to 360 mg most preferably 360 mg per day of a lipase inhibitor is administered to a subject preferably in divided doses two or particularly three times per day the subject is preferably an obese or overweight.